Comparison of Therapeutic Efficacy and Urodynamic Findings of Solifenacin Succinate versus Mirabegron in Women with Overactive Bladder Syndrome: Results of a Randomized Controlled Study

Publisher： Karger

E-ISSN： 1423-0399|97|3|325-329

ISSN： 0042-1138

Source： Urologia Internationalis, Vol.97, Iss.3, 2016-04, pp. : 325-329

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Long-Term Safety and Efficacy of Two Different Antimuscarinics, Imidafenacin and Solifenacin, for Treatment of Overactive Bladder: A Prospective Randomized Controlled Study

By  

Urologia Internationalis, Vol. 90, Iss. 2, 2012-11 ,pp. : 161-167

Karger

Access to resources Recommend Favorite

Efficacy and Safety of the Selective β3‐Adrenoceptor Agonist Mirabegron in Japanese Patients with Overactive Bladder: A Randomized, Double‐Blind, Placebo‐Controlled, Dose‐Finding Study

By  

LUTS, Vol. 7, Iss. 2, 2015-05 ,pp. : 84-92

John Wiley & Sons Inc

Access to resources Recommend Favorite

Results of a randomized, double‐blind, parallel‐group, placebo‐ and active‐controlled, multicenter study of mirabegron, a β3‐adrenoceptor agonist, in patients with overactive bladder in Asia

By  

NEUROUROLOGY AND URODYNAMICS, Vol. 34, Iss. 7, 2015-09 ,pp. : 685-692

John Wiley & Sons Inc

Access to resources Recommend Favorite

Safety and efficacy of mirabegron as ‘add‐on’ therapy in patients with overactive bladder treated with solifenacin: a post‐marketing, open‐label study in Japan (MILAI study)

By  

BJU INTERNATIONAL, Vol. 116, Iss. 4, 2015-10 ,pp. : 612-622

John Wiley & Sons Inc

Access to resources Recommend Favorite

Combination of solifenacin and mirabegron for overactive bladder management

By  

BJU INTERNATIONAL, Vol. 116, Iss. 4, 2015-10 ,pp. : 498-499

John Wiley & Sons Inc

Access to resources Recommend Favorite